A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

NCT01371617 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Fibrosis, Bone Marrow

Interventions

DRUG: IPI-926

Sponsor

Infinity Pharmaceuticals, Inc.